Newcomer misses noninferiority mark against established GLP-1 receptor agonist

Once-daily liraglutide slightly outperformed once-weekly albiglutide in a head-to-head trial in adults with poorly controlled type 2 diabetes, researchers reported in the April issue of the Lancet...